In addition, pooled results from two studies indicated that elevated CD163+ TAMs were more prone to advanced tumor-stage with a fixed-effects model (OR: 4.11, 95% CI 2.12–7.96) (Figure 3F). Here, CD163 is linked to neoplasm.